Retatrutide is a next-generation obesity drug that simultaneously activates three hormonal pathways — GLP-1, GIP, and glucagon receptors — surpassing the effectiveness of current dual-agonist treatments like tirzepatide. Phase 2 clinical trials report weight reductions comparable to bariatric surgery, alongside meaningful improvements in metabolic conditions including NASH and cardiovascular disease. This review frames retatrutide as a landmark advance in rational drug design, where engineering a single molecule to mimic multiple gut hormones produces synergistic metabolic benefits. Authors also highlight the need for equitable access policies and healthcare system preparation as this class of therapy matures toward broader clinical use.
